The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Here's how to relieve the itching and get steps on preventing hives and avoiding your triggers. As small as jujubes or as large as saucers, hives are an allergic reaction that take the form of itchy ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...